Compare Biogen Inc (BIIB) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Norfolk Southern Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Norfolk Southern Corporation trades at $335.84 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 2.5× Biogen Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NSC | |
|---|---|---|
Market Cap | $30.13B | $75.15B |
Sector | Health | Technology |
52-Week High | $216.63 | $350.66 |
52-Week Low | $128.93 | $272.35 |
Enterprise Value | $37.20B | $90.70B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Norfolk Southern (NSC) trades at $334.44, up 0.15% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including three consecutive quarterly earnings beats, a net income margin of 21.02%, and robust cash flow from operations of $4.36B in 2025. Recent news highlights merger developments with Union Pacific and positive Q2 2026 results driven by freight demand.
Outlook is positive with a consensus price target of $369.67, implying upside, but risks include high valuation (P/E 28.55), merger regulatory scrutiny, and fuel cost pressures. Institutional sentiment is mixed with 43.75% buy ratings, yet hedge fund activity suggests potential momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
